Home » Stocks » Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. (ALXN)

Stock Price: $101.24 USD -0.64 (-0.63%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $101.35 +0.11 (0.11%) Aug 11, 5:53 PM

Stock Price Chart

Key Info

Market Cap 22.19B
Revenue (ttm) 5.54B
Net Income (ttm) 846.10M
Shares Out 219.17M
EPS (ttm) 3.81
PE Ratio 26.57
Forward PE 9.60
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $101.24
Previous Close $101.88
Change ($) -0.64
Change (%) -0.63%
Day's Open 102.86
Day's Range 101.10 - 102.86
Day's Volume 1,511,755
52-Week Range 72.67 - 125.52

More Stats

Market Cap 22.19B
Enterprise Value 21.95B
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date n/a
Shares Outstanding 219.17M
Float 218.56M
EPS (basic) 3.77
EPS (diluted) 3.81
FCF / Share 10.73
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.76%
FCF Yield 10.66%
Payout Ratio n/a
Shares Short 4.76M
Short Ratio 2.33
Short % of Float 2.10%
Beta 1.39
PE Ratio 26.57
Forward PE 9.60
P/FCF Ratio 9.38
PS Ratio 4.01
PB Ratio 2.13
Revenue 5.54B
Operating Income 452.10M
Net Income 846.10M
Free Cash Flow 2.37B
Net Cash 244.00M
Net Cash / Share 1.11
Gross Margin 83.02%
Operating Margin 8.17%
Profit Margin 15.30%
FCF Margin 42.73%
ROA 10.27%
ROE 8.19%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (22)

Buy 10
Overweight 3
Hold 9
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(41.53% upside)
Current: $101.24
Target: 143.28
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth20.81%16.34%15.14%18.44%16.56%44%36.79%44.76%44.82%-
Gross Profit4,5973,7573,0972,8262,3712,0601,3741,061690477
Operating Income2,132386668703601889532404231151
Net Income2,40477.6044339914465725325517597.03
Shares Outstanding223223224224213198196190183179
Earnings Per Share10.700.351.971.760.673.
EPS Growth2957.14%-82.23%11.93%162.69%-79.45%156.69%-0.78%40.66%75%-
Operating Cash Flow2,0854261,1161,086675640497411270161
Capital Expenditures-155-213-357-333-286-137-29.33-21.85-21.98-12.84
Free Cash Flow1,930213758754389503468389248148
Cash & Equivalents2,7501,5641,4741,2931,3851,9621,515990541362
Total Debt2,6663,2073,2313,2893,571165145149-5.18
Net Cash / Debt83.70-1,643-1,757-1,995-2,1861,7971,370841541356
Book Value11,2729,1658,8938,6948,2593,3022,3821,9711,134860
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alexion Pharmaceuticals, Inc.
Country United States
Employees 3,082
CEO Ludwig N. Hantson

Stock Information

Ticker Symbol ALXN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALXN
IPO Date February 28, 1996


Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.